Radium-223 therapy for bone metastasis from prostate cancer
NGHT has had to publish a VEAT notice for the following therapy: Xofigo (Radium 223) Dose. The reason for the VEAT notice was due to: "There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years. This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the s...
Buyer
Northampton General Hospital N H S Trust
Value
£2,200,000
Published
22 Dec 2016
Closes
3 Dec 2016
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Selective
Category
Goods
Contract starts
22 Dec 2016
Contract ends
3 Sept 2020
CPV classifications
85000000
Health and social work services
Lots
Lot default Radium-223 therapy for bone metastasis from prostate cancer
£1,500,000
NGHT has had to publish a VEAT notice for the following therapy: Xofigo (Radium 223) Dose. The reason for the VEAT notice was due to: "There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years. This new treatment (Radium 223) has...
Delivery: East Midlands · United Kingdom, East Midlands, United Kingdom
Documents
Unlock document linkOpportunity notice on Contracts Finder
28 Nov 2016
Opportunity notice on Contracts Finder
Tender notice · Web page
Awarded contract notice on Contracts Finder
22 Dec 2016
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.